SCHEMBL2897767

SCHEMBL2897767

CCCCCCCCC=CCCCCCCCC(=O)C(=O)C(F)(F)F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.70
CES1 P23141 2/20 0.70
FABP3 P05413 5/20 0.61
TERT O14746 3/20 0.58
CYP1A2 P05177 2/20 0.58
MAPT P10636 2/20 0.58
CYP2C19 P33261 2/20 0.58
BLM P54132 2/20 0.58
HSD17B10 Q99714 2/20 0.58
FABP4 P15090 2/20 0.58
PTPN1 P18031 2/20 0.58
PPARG P37231 2/20 0.58
KMT2A Q03164 2/20 0.58
PPARD Q03181 2/20 0.58
PPARA Q07869 2/20 0.58
GMNN O75496 1/20 0.58
USP2 O75604 1/20 0.58
LMNA P02545 1/20 0.58
POLB P06746 1/20 0.58
CYP2C9 P11712 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897766 1.00 FAAH (0.70) FAAHCES1FABP3TERTCYP1A2
SCHEMBL2827382 0.90 FAAH (0.71) FAAHCES1FABP3MAPTBLM
SCHEMBL29794313 0.89 CES1 (0.63) FAAHCES1CYP1A2HSD17B10KMT2A
SCHEMBL1334928 0.89 CES1 (0.63) FAAHCES1CYP1A2HSD17B10KMT2A
SCHEMBL20600305 0.83 FAAH (0.78) FAAHFABP3TERTCYP1A2MAPT
SCHEMBL15400706 0.83 FAAH (0.78) FAAHFABP3TERTCYP1A2MAPT
SCHEMBL24938529 0.82 FAAH (1.00) FAAHCES1TERTCYP1A2MAPT
SCHEMBL4085373 0.82 FAAH (1.00) FAAHCES1TERTCYP1A2MAPT
SCHEMBL24938531 0.82 FAAH (1.00) FAAHCES1TERTCYP1A2MAPT
SCHEMBL8059738 0.82 FAAH (1.00) FAAHCES1TERTCYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240085429-A1 ALTERING PROTEIN FUNCTION BY PHARMACOLOGICAL TARGETING OF MEMBRANE DOMAINS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-03-14 US disclosed
US-10156566-B2 Detoxification of microbial virulence factors in oral cavity THE PROCTER & GAMBLE COMPANY (US) 2018-12-18 US disclosed
EP-3292215-A1 DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY The Procter and Gamble Company (US) 2018-03-14 EP disclosed
US-20170119643-A1 DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY THE PROCTER & GAMBLE COMPANY 2017-05-04 US disclosed
WO-2016179561-A1 DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY THE PROCTER & GAMBLE COMPANY (US) 2016-11-10 WO disclosed
US-8263558-B2 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins ABBOTT LABORATORIES (US) 2012-09-11 US disclosed
EP-1370867-B1 PROTEIN PROFILING PLATFORM ACTIVX BIOSCIENCES INC (US) 2010-08-04 EP disclosed
US-20090214515-A1 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-08-27 US disclosed
EP-1963363-A2 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS Abbott Laboratories (US) 2008-09-03 EP disclosed
EP-1572311-A4 ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2007-12-12 EP disclosed
EP-1370867-A1 PROTEIN PROFILING PLATFORM Activx Biosciences, Inc. (US) 2003-12-17 EP disclosed
EP-1275006-A2 PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES The Scripps Research Institute (US) 2003-01-15 EP disclosed
US-20020182652-A1 Proteomic analysis NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2002-12-05 US disclosed
US-20020182651-A1 Protein profiling platform ACTIVX BIOSCIENCES, INC. 2002-12-05 US disclosed
WO-2002071066-A1 PROTEIN PROFILING PLATFORM ACTIVX BIOSCIENCES, INC. (US) 2002-09-12 WO disclosed
US-20020064799-A1 Proteomic analysis THE SCRIPPS RESEARCH INSTITUTE OF AN ASSIGNMENT 2002-05-30 US disclosed
US-20020045194-A1 Proteomic analysis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-04-18 US disclosed
US-20020040275-A1 Proteomic analysis THE SCRIPPS RESEARCH INSTITUTE 2002-04-04 US disclosed
WO-2001077668-A2 PROTEOMIC ANALYSIS USING ACTIVE-SITE DIRECTED PROBES THE SCRIPPS RESEARCH INSTITUTE (US) 2001-10-18 WO disclosed
WO-2001077684-A2 PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES THE SCRIPPS RESEARCH INSTITUTE (US) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170119643-A1 DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY GSTM2, GSTA2, GSTA1 FAAH 2168/4885CES1 842/4885FABP3 1257/4885
US-10156566-B2 Detoxification of microbial virulence factors in oral cavity GSTM2, GSTA2, GSTA1 FAAH 2168/4885CES1 842/4885FABP3 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.